



Life Sciences & Healthcare

Inside this issue:

Public Market Overview - Public Equity Values, Debt to Value and Earnings, Market Multiples, Discount Rates and Implied Earnings Growth Rates

M&A Transaction Summary - Multiples & Discount Rates, and Noted Transactions

Private Equity & VC Summary - With Noted Transactions

Public Debt & Equity Underwriting Summary - With Noted Transactions

Selected Life Sciences & Healthcare 2008 Highlights for The Salter Group

Page

2


7

9

11

13

Exhibit 1.1—Life Sciences & Healthcare Indices



Key Observations:

The charts and graphs contained within this newsletter depict the state and direction of the Life Sciences & Healthcare industry. The key observations are summarized as follows:

1. Market Values - Overall market values have decreased 17% in the past year while having rebounded 3% within the past 3 months, with Healthcare Technology's 25% as the highest observed increase in growth in the last three months.
2. Goodwill Impairment - Increased market values over the past three months have significantly reduced the risk of impairment among Life Sciences & Healthcare companies.
3. Market Multiples - Valuation multiples have improved compared to last year due to an increase in growth expectations. However, the cost of capital has slightly increased reflecting a higher risk return requirement by investors.
4. M&A Transaction Activity – Increased activity in the first half was driven by larger cash-rich and credit-worthy pharmaceutical companies seeking to acquire smaller companies with new products and access to growing economies as pharmaceutical companies prepare for patents on drugs to expire and new drugs in the pipeline begin to decline.
5. Private Equity and VC Activity - Overall activity has increased in the past three months due to (i) the Obama's administration's focus on healthcare reform has triggered investments into companies that can potentially take advantage of stimulus funds and serve the future rise in healthcare costs (ii) larger healthcare & life science companies' recent surge in acquisitions opens exit opportunities for investors in smaller and underfunded companies.
6. Debt and Equity Underwriting Activity - Underwriting activity of equity and debt increased significantly compared to last year as public offerings have filled some of the void in commercial bank financing. The pharmaceutical sector experienced the greatest growth in underwriting activity mainly due to Pfizer's offering of \$11 billion to help fund its acquisition of Wyeth.
7. Overall, the markets have improved but remain well below levels observed one and two years ago as (i) recessionary conditions continue to pressure earnings growth expectations and (ii) commercial bank illiquidity continues to impact growth financing and M&A activity.

Exhibit 1.2—Change in Worldwide Public Company Enterprise Values (\$MM)

Enterprise Value	06/30/09	05/31/09	03/31/09	06/30/08	06/30/07
Facilities	\$52,404	\$49,818	\$45,106	\$62,700	\$58,158
% Change	<i>n/a</i>	5.2%	16.2%	-16.4%	-9.9%
Longterm Care	\$21,687	\$20,330	\$18,235	\$29,678	\$31,486
% Change	<i>n/a</i>	6.7%	18.9%	-26.9%	-31.1%
Managed Healthcare	101,021	91,676	83,632	148,454	198,461
% Change	<i>n/a</i>	10.2%	20.8%	-32.0%	-49.1%
Healthcare Services	\$131,464	\$127,690	\$120,728	\$152,126	\$139,880
% Change	<i>n/a</i>	3.0%	8.9%	-13.6%	-6.0%
Healthcare Technology	\$23,147	\$22,100	\$18,504	\$24,338	\$28,657
% Change	<i>n/a</i>	4.7%	25.1%	-4.9%	-19.2%
Biologicals	\$343,841	\$324,232	\$308,632	\$401,403	\$394,969
% Change	<i>n/a</i>	6.0%	11.4%	-14.3%	-12.9%
Pharmaceuticals	\$1,483,235	\$1,464,307	\$1,378,026	\$1,769,802	\$2,004,165
% Change	<i>n/a</i>	1.3%	7.6%	-16.2%	-26.0%
Diagnostics	\$129,923	\$123,442	\$116,918	\$157,227	\$143,871
% Change	<i>n/a</i>	5.3%	11.1%	-17.4%	-9.7%
Equipment & Supplies	\$107,186	\$102,135	\$87,697	\$136,372	\$133,191
% Change	<i>n/a</i>	4.9%	22.2%	-21.4%	-19.5%
Therapeutics	\$217,260	\$213,190	\$189,478	\$274,407	\$285,232
% Change	<i>n/a</i>	1.9%	14.7%	-20.8%	-23.8%
Total	\$2,611,169	\$2,538,919	\$2,366,958	\$3,156,508	\$3,418,070
% Change	<i>n/a</i>	2.8%	10.3%	-17.3%	-23.6%

Exhibit 1.3 - Debt to Market Cap vs. Book Value

Aggregate Debt/Equity BV	06/30/09	06/30/08	06/30/07
Facilities	192.5%	212.3%	173.6%
Longterm Care	207.6%	182.7%	168.2%
Managed Healthcare	47.5%	48.6%	31.8%
Healthcare Services	84.6%	89.9%	74.7%
Healthcare Technology	69.1%	79.6%	80.7%
Biologicals	37.4%	41.5%	41.6%
Pharmaceuticals	51.3%	36.6%	31.3%
Diagnostics	59.1%	36.6%	31.3%
Equipment & Supplies	40.5%	42.8%	45.0%
Therapeutics	53.4%	49.0%	47.8%
Aggregate Debt/Market Cap			
Facilities	111.4%	83.1%	47.6%
Longterm Care	164.8%	84.7%	52.1%
Managed Healthcare	38.2%	25.7%	11.3%
Healthcare Services	33.3%	28.6%	22.4%
Healthcare Technology	24.6%	25.3%	16.1%
Biologicals	12.2%	11.0%	10.1%
Pharmaceuticals	20.4%	13.3%	9.0%
Diagnostics	19.5%	15.3%	13.2%
Equipment & Supplies	14.4%	11.6%	9.7%
Therapeutics	22.1%	15.4%	12.8%

Source: Capital IQ

Exhibit 1.4 - EBITDA to Aggregate Sector Debt

EBITDA/Aggregate Debt	06/30/09	06/30/08	06/30/07
Facilities	23.2%	20.8%	25.1%
Longterm Care	15.7%	14.2%	16.4%
Managed Healthcare	56.9%	69.9%	97.0%
Healthcare Services	43.3%	38.3%	44.6%
Healthcare Technology	43.3%	33.4%	41.5%
Biologicals	38.5%	28.5%	21.6%
Pharmaceuticals	71.4%	85.9%	98.4%
Diagnostics	59.5%	57.9%	60.0%
Equipment & Supplies	64.7%	60.0%	59.0%
Therapeutics	57.7%	59.4%	57.8%

Exhibit 1.5– Key Public Market Measures (\$MM)

	As of	
	06/30/09	6/30/2008
Enterprise Value		
N. America	\$1,500,523	\$1,745,471
Europe	\$897,620	\$1,122,972
Asia Pacific	\$222,533	\$250,512
Aggregate Debt		
N. America	\$285,476	\$272,436
Europe	\$207,739	\$169,920
Asia Pacific	\$35,112	\$30,700
Aggregate Net Sales		
N. America	\$1,211,256	\$1,155,635
Europe	\$453,704	\$482,799
Asia Pacific	\$216,891	\$203,452

	As of	
	06/30/09	6/30/2008
EV/Net Sales		
N. America	2.56 x	3.26 x
Europe	2.52 x	3.33 x
Asia Pacific	2.20 x	2.35 x
EV/EBIT		
N. America	11.69 x	13.95 x
Europe	10.70 x	13.13 x
Asia Pacific	14.79 x	13.27 x
Cost of Equity		
N. America	9.3%	8.9%
Europe	9.2%	8.2%
Asia Pacific	9.3%	9.4%
Implied Earnings Growth		
N. America	0.0%	1.0%
Europe	-0.2%	1.2%
Asia Pacific	0.8%	1.0%

Source: Capital IQ

Exhibit 1.6—Enterprise Value to Revenue Multiples

	As of	Historical		
	06/30/09	3/31/2009	6/30/2008	6/30/2006
Facilities				
N. America	1.04 x	0.93 x	1.18 x	1.00 x
Europe	1.36 x	1.26 x	1.42 x	0.99 x
Asia Pacific	1.38 x	1.22 x	1.26 x	1.18 x
Longterm Care				
N. America	0.73 x	0.66 x	0.93 x	0.77 x
Europe	0.78 x	0.73 x	0.86 x	0.40 x
Asia Pacific	4.46 x	4.14 x	4.86 x	3.80 x
Managed Healthcare				
N. America	0.37 x	0.33 x	0.45 x	0.65 x
Europe	N/A	N/A	N/A	N/A
Asia Pacific	N/A	N/A	N/A	N/A
Healthcare Services				
N. America	0.81 x	0.71 x	0.84 x	0.73 x
Europe	1.73 x	1.59 x	1.75 x	1.56 x
Asia Pacific	1.17 x	1.06 x	1.12 x	0.96 x
Healthcare Technology				
N. America	2.31 x	1.74 x	1.90 x	2.03 x
Europe	0.60 x	0.51 x	0.72 x	1.08 x
Asia Pacific	2.37 x	2.11 x	2.59 x	0.65 x
Biologicals				
N. America	4.16 x	3.93 x	4.83 x	4.35 x
Europe	2.70 x	2.32 x	3.19 x	1.80 x
Asia Pacific	3.49 x	3.40 x	3.94 x	2.32 x
Pharmaceuticals				
N. America	1.16 x	1.11 x	1.33 x	1.41 x
Europe	1.96 x	1.92 x	2.19 x	2.49 x
Asia Pacific	0.83 x	0.75 x	1.01 x	0.93 x
Diagnostics				
N. America	2.45 x	2.26 x	2.96 x	2.09 x
Europe	1.85 x	1.67 x	2.29 x	0.27 x
Asia Pacific	1.11 x	0.92 x	1.37 x	1.16 x
Equipment & Services				
N. America	1.56 x	1.29 x	1.87 x	1.36 x
Europe	2.48 x	2.05 x	3.20 x	2.75 x
Asia Pacific	0.86 x	0.79 x	0.87 x	0.94 x
Therapeutics				
N. America	2.48 x	2.21 x	3.27 x	2.91 x
Europe	1.79 x	1.60 x	1.75 x	1.56 x
Asia Pacific	2.00 x	1.76 x	2.29 x	2.12 x

Source: Capital IQ

Exhibit 1.7—Enterprise Value to EBITDA Multiples

	As of		Historical	
	06/30/09	3/31/2009	6/30/2008	6/30/2006
Facilities				
N. America	7.01 x	6.45 x	8.84 x	9.68 x
Europe	10.27 x	9.63 x	10.97 x	9.62 x
Asia Pacific	9.98 x	8.80 x	9.31 x	11.16 x
Longterm Care				
N. America	8.34 x	7.64 x	12.08 x	11.52 x
Europe	9.83 x	9.20 x	11.20 x	6.61 x
Asia Pacific	60.74 x	58.53 x	66.65 x	44.71 x
Managed Healthcare				
N. America	5.07 x	4.62 x	5.18 x	9.14 x
Europe	N/A	N/A	N/A	N/A
Asia Pacific	N/A	N/A	N/A	N/A
Healthcare Services				
N. America	8.91 x	7.95 x	10.44 x	11.58 x
Europe	9.33 x	8.55 x	9.80 x	13.88 x
Asia Pacific	11.97 x	10.99 x	13.18 x	14.64 x
Healthcare Technology				
N. America	14.03 x	10.30 x	13.62 x	16.47 x
Europe	6.42 x	5.40 x	7.54 x	10.21 x
Asia Pacific	9.46 x	8.38 x	12.32 x	6.11 x
Biologicals				
N. America	15.38 x	15.29 x	22.41 x	28.15 x
Europe	30.64 x	27.18 x	60.35 x	352.82 x
Asia Pacific	17.20 x	16.68 x	20.66 x	49.37 x
Pharmaceuticals				
N. America	7.22 x	7.08 x	9.27 x	11.00 x
Europe	6.96 x	6.98 x	8.44 x	11.40 x
Asia Pacific	7.30 x	6.56 x	8.55 x	12.27 x
Diagnostics				
N. America	10.09 x	9.37 x	13.31 x	12.90 x
Europe	7.75 x	6.94 x	11.19 x	1.32 x
Asia Pacific	10.50 x	8.53 x	9.83 x	11.39 x
Equipment & Services				
N. America	12.49 x	10.77 x	18.23 x	18.98 x
Europe	11.62 x	9.62 x	15.45 x	15.11 x
Asia Pacific	6.83 x	6.26 x	7.54 x	8.84 x
Therapeutics				
N. America	9.16 x	8.15 x	12.84 x	13.31 x
Europe	9.15 x	8.16 x	9.75 x	11.75 x
Asia Pacific	10.57 x	9.10 x	11.38 x	13.23 x

Source: Capital IQ

Exhibit 2.1—M&A Transaction Volume and Values - Through 6/30 (\$MM)

	2009	2008	2007	2006	2005
M&A Transaction Volume					
Facilities	21	77	88	56	54
Longterm Care	12	43	42	46	40
Managed Healthcare	2	8	11	9	12
Healthcare Services	24	174	207	117	110
Healthcare Technology	20	61	54	36	30
Biologicals	28	109	108	92	81
Pharmaceuticals	41	161	147	146	150
Diagnostics	13	28	57	47	35
Equipment & Supplies	16	76	112	93	69
Therapeutics	18	48	37	39	32
Total Deal Count	195	785	863	681	613
M&A Transaction Values					
Facilities	\$966	\$5,074	\$25,049	\$45,843	\$16,060
Longterm Care	\$416	\$2,600	\$13,239	\$33,705	\$6,184
Managed Healthcare	\$344	\$7,164	\$28,700	\$1,863	\$17,983
Healthcare Services	\$197	\$15,156	\$17,281	\$13,640	\$8,604
Healthcare Technology	\$208	\$4,744	\$4,735	\$1,866	\$2,280
Biologicals	\$50,453	\$40,202	\$43,788	\$35,832	\$7,691
Pharmaceuticals	\$6,124	\$76,988	\$77,109	\$78,949	\$54,290
Diagnostics	\$3,040	\$1,812	\$28,222	\$9,597	\$5,885
Equipment & Supplies	\$343	\$20,346	\$20,316	\$8,710	\$6,995
Therapeutics	\$4,035	\$12,812	\$23,741	\$38,458	\$3,980
Total Deal Value	\$66,124	\$186,899	\$282,179	\$268,462	\$129,951

Exhibit 2.2—Key M&A Multiples - Through 6/30

	2009	2008	2007	2006	2005
EV/EBIT:					
Facilities	8.94 x	26.69 x	16.60 x	13.46 x	20.33 x
Longterm Care	20.41 x	23.82 x	20.02 x	21.58 x	38.93 x
Managed Healthcare	8.71 x	9.99 x	14.58 x	11.40 x	11.90 x
Healthcare Services	8.74 x	20.09 x	24.11 x	23.32 x	23.88 x
Healthcare Technology	9.64 x	25.57 x	39.66 x	N/A	N/A
Biologicals	19.66 x	32.44 x	N/A	33.02 x	20.28 x
Pharmaceuticals	16.18 x	20.63 x	25.46 x	22.08 x	17.83 x
Diagnostics	17.14 x	26.57 x	35.52 x	20.92 x	19.43 x
Equipment & Supplies	N/A	21.23 x	24.90 x	27.50 x	24.81 x
Therapeutics	18.03 x	27.26 x	31.96 x	37.80 x	34.02 x
EV/EBITDA:					
Facilities	6.89 x	19.05 x	12.22 x	9.17 x	14.88 x
Longterm Care	N/A	16.46 x	13.90 x	13.65 x	26.14 x
Managed Healthcare	8.00 x	10.77 x	13.43 x	9.82 x	10.52 x
Healthcare Services	N/A	15.50 x	16.05 x	17.17 x	14.04 x
Healthcare Technology	2.81 x	18.16 x	16.04 x	22.82 x	N/A
Biologicals	17.49 x	N/A	N/A	20.25 x	15.77 x
Pharmaceuticals	11.73 x	17.48 x	16.84 x	27.63 x	14.43 x
Diagnostics	10.09 x	28.96 x	25.78 x	13.45 x	14.97 x
Equipment & Supplies	N/A	18.99 x	14.49 x	15.88 x	15.16 x
Therapeutics	14.37 x	23.57 x	25.48 x	29.94 x	N/A

Source: Capital IQ

Life Sciences & Healthcare M&A Summary - Noted Transactions

Second Quarter 2009

Exhibit 3 - Noted 2008 and 2009 M&A Transactions - Through 6/30 (\$MM)

Group	Buyer	Target	Amount	Target Territory
Facilities	Khazanah Nasional Berhad	Parkway Holdings Ltd.	\$390.7	Singapore
	MPT Operating Partnership LP	HCP Inc., 21 Healthcare Facilities	\$357.2	United States
	3i Group PLC	Ultralase Limited	\$347.3	United Kingdom
Longterm Care	Advent International Corporation	Craegmoor Healthcare Co. Ltd.	\$578.7	United Kingdom
	Cofinimmo SA	Cofinimmo France SA	\$334.5	France
	Emeritus Corp.	Nationwide Health Properties Inc., 24 Communities	\$305.0	United States
Managed Healthcare	Unitedhealth Group, Inc.	Sierra Health Services Inc.	\$2,544.2	United States
	Bupa Australia Health Pty Ltd.	MBF Australia Limited	\$2,183.3	Australia
	Connecticut General Life Insurance Company Inc.	Great-West Healthcare Inc.	\$1,600.0	United States
Healthcare Services	Primary Health Care Ltd.	Symbion Health Limited	\$2,530.2	Australia
	The Blackstone Group, Private Equity Group	Apria Healthcare Group Inc.	\$1,593.6	United States
	Inverness Medical Innovations Inc.	Matria Healthcare Inc.	\$1,142.7	United States
Healthcare Technology	Multiple	TriZetto Group Inc.	\$1,421.0	United States
	Computer Sciences Corporation	First Consulting Group Inc.	\$369.0	United States
	Nuance Communications Inc.	eScripton, Inc.	\$368.1	United States
Biologicals	Roche Holdings Inc.	Genentech Inc.	\$46,722.3	United States
	Takeda Pharmaceutical Co. Ltd.	Millennium Pharmaceuticals Inc.	\$8,689.3	United States
	Eli Lilly & Co.	ImClone Systems Incorporated	\$7,133.6	United States
Pharmaceuticals	Kyorin Pharmaceutical Co. Ltd.	Nisshin Kyorin Pharmaceutical Co. Ltd.	\$30,374.5	Japan
	Teva Pharmaceutical Industries Limited	Barr Pharmaceuticals, Inc.	\$9,467.4	United States
	Eisai Corporation of North America	MGI PHARMA Inc.	\$3,871.9	United States
Diagnostics	Abbott Laboratories	Advanced Medical Optics Inc.	\$2,769.8	United States
	Avista Capital Holdings LP	Lantheus Medical Imaging Inc.	\$525.0	United States
	Avista Capital Holdings LP	Boston Scientific Corp. (Fluid Management And Venous Access Businesses)	\$415.0	United States
Equipment & Supplies	Novartis AG	Alcon Inc.	\$10,605.4	Switzerland
	Multiple	ConvaTec Inc.	\$4,100.0	United States
	Multiple	Tunstall Group Ltd.	\$1,024.6	United Kingdom
Therapeutics	Philips Holding USA Inc.	Respironics Inc.	\$5,177.0	N. America
	Olympus Corporation	Gyrus Group PLC	\$2,149.9	Europe
	N/A	Advanced Bionics Corporation	\$1,450.0	N. America

Source: Capital IQ

Life Sciences & Healthcare
Private Equity & VC Investment Summary

Second Quarter 2009

Exhibit 4 - PE & VC Deals Count & Dollar Volume - Through 6/30 (\$MM)

	2009	2008	2007	2006	2005
PE & VC Transaction Volume					
Facilities	7	10	15	13	11
Longterm Care	1	4	2	1	3
Managed Healthcare	1	1	5	3	2
Healthcare Services	19	33	35	31	37
Healthcare Technology	35	71	74	84	59
Biologicals	111	280	276	252	192
Pharmaceuticals	74	182	228	198	159
Diagnostics	35	83	80	71	71
Equipment & Supplies	27	102	85	66	32
Therapeutics	40	98	112	107	77
Total Deal Count	350	864	912	826	643
PE & VC Transaction Values					
Facilities	\$54	\$225	\$469	\$256	\$139
Longterm Care	\$8	\$101	\$64	\$9	\$38
Managed Healthcare	\$4	\$5	\$81	\$23	\$13
Healthcare Services	\$165	\$842	\$707	\$639	\$554
Healthcare Technology	\$120	\$499	\$609	\$488	\$347
Biologicals	\$1,254	\$3,518	\$3,332	\$3,080	\$2,489
Pharmaceuticals	\$1,179	\$3,068	\$4,764	\$3,446	\$2,774
Diagnostics	\$254	\$695	\$741	\$526	\$583
Equipment & Supplies	\$401	\$932	\$838	\$563	\$304
Therapeutics	\$632	\$1,443	\$2,101	\$1,420	\$883
Total Deal Value	\$4,069	\$11,328	\$13,705	\$10,450	\$8,123

Source: Capital IQ

Life Sciences & Healthcare
Private Equity & VC Noted Transactions

Second Quarter 2009

Exhibit 5- Noted 2008 and 2009 PE & VC Transactions - Through 6/30 (\$MM)

Group	Buyer	Target	Amount	Target Territory
Facilities	Lindsay Goldberg	Ambulatory Services of America Inc.	\$75.0	N. America
	Multiple	Senior Living Group NV	\$42.1	Europe
	Multiple	Valoriza Servicios Socio Sanitarios	\$8.4	Europe
Longterm Care	Multiple	Holding Sanità e Servizi Spa	\$80.8	Europe
	Waterland Private Equity Investments BV	Senior Living Group NV	\$60.6	Europe
	Multiple	Valoriza Servicios Socio Sanitarios	\$12.1	Europe
Managed Healthcare	Multiple	Generation Health Inc.	\$5.0	N. America
	Santé Ventures	Hospitalists Now Inc.	\$3.5	N. America
Healthcare Services	Multiple	Labco	\$529.9	Europe
	N/A	PRWT Services Inc.	\$53.0	N. America
	Multiple	Precision Therapeutics Inc.	\$43.0	N. America
Healthcare Technology	Multiple	The HealthCentral Network Inc.	\$50.0	N. America
	Bain Capital Ventures	MedeFinance Inc.	\$50.0	N. America
	Multiple	CodeRyte Inc.	\$47.2	N. America
Biologicals	Multiple	OncoMed Pharmaceuticals Inc.	\$169.0	N. America
	Multiple	Pacific Biosciences Inc.	\$120.0	N. America
	Multiple	Amyris Biotechnologies Inc.	\$91.4	N. America
Pharmaceuticals	TPG Growth	NT Pharma LLC	\$193.0	N. America
	Multiple	GANYMED Pharmaceuticals AG	\$131.3	Europe
	Multiple	Sagent Pharmaceuticals Inc.	\$113.0	N. America
Diagnostics	Multiple	mtm laboratories AG	\$44.3	Europe
	Multiple	SuperSonic Imagine SA	\$36.4	Europe
	Multiple	Glaukos Corporation	\$35.0	N. America
Equipment & Supplies	Multiple	Valeritas Inc.	\$87.0	N. America
	Multiple	TV2 Holding Company	\$65.0	N. America
	Multiple	Ardian Inc.	\$47.0	N. America
Therapeutics	Multiple	Small Bone Innovations Inc.	\$108.0	N. America
	Multiple	CVRx Inc.	\$84.0	N. America
	American Capital Ltd.	Avalon Laboratories LLC	\$66.0	N. America

Source: Capital IQ

Life Sciences & Healthcare
Debt & Equity Underwriting Summary

Second Quarter 2009

Exhibit 6– Debt & Equity Underwriting Activity - Through 6/30 (\$MM)

	2009	2008	2007	2006	2005
Underwriting Volume					
Facilities	-	3	5	5	2
Longterm Care	2	-	2	5	4
Managed Healthcare	4	8	10	7	8
Healthcare Services	7	9	18	17	20
Healthcare Technology	2	-	9	10	4
Biologicals	21	49	117	180	180
Pharmaceuticals	24	15	62	67	55
Diagnostics	7	5	12	16	18
Equipment & Supplies	7	4	19	24	29
Therapeutics	5	1	21	35	23
Total Deal Count	79	94	275	366	343
Underwriting Value					
Facilities	\$0	\$347	\$722	\$1,914	\$376
Longterm Care	\$170	\$0	\$342	\$1,217	\$419
Managed Healthcare	\$1,696	\$4,528	\$2,778	\$1,698	\$6,821
Healthcare Services	\$5,151	\$1,864	\$1,339	\$797	\$3,567
Healthcare Technology	\$90	\$0	\$687	\$480	\$308
Biologicals	\$3,335	\$4,450	\$4,207	\$9,271	\$7,208
Pharmaceuticals	\$23,436	\$3,696	\$35,316	\$6,250	\$3,863
Diagnostics	\$1,850	\$658	\$4,645	\$1,067	\$303
Equipment & Supplies	\$1,119	\$340	\$1,365	\$1,005	\$1,708
Therapeutics	\$1,259	\$20	\$1,098	\$3,021	\$1,708
Total Deal Value	\$38,105	\$15,903	\$52,500	\$26,719	\$26,282
Security Type					
Equity	\$1,849	\$806	\$14,157	\$8,863	\$8,019
Debt	\$32,921	\$10,299	\$33,390	\$6,657	\$10,614
Total Value	\$34,770	\$11,106	\$47,547	\$15,520	\$18,633

Source: Capital IQ

Life Sciences & Healthcare
Debt & Equity Underwriting Noted Transactions

Second Quarter 2009

Exhibit 7- Noted 2008 and 2009 Transactions - Through 6/30 (\$MM)

Group	Issuer	Net Amount	Issuer Territory
Facilities	HEALTHSOUTH Corp.	\$150.2	N. America
	Universal Health Services Inc.	\$150.2	N. America
	Hanger Orthopedic Group Inc.	\$44.0	N. America
Long Term Care	Brookdale Senior Living Inc.	\$142.9	N. America
	Metlifecare Ltd.	\$19.7	Asia Pacific
Managed Healthcare	Unitedhealth Group Inc.	\$1,091.8	N. America
	Unitedhealth Group Inc.	\$1,073.6	N. America
	WellPoint Inc.	\$595.1	N. America
Healthcare Services	Express Scripts Inc.	\$1,364.4	N. America
	MedcoHealth Solutions Inc.	\$1,179.7	N. America
	Express Scripts Inc.	\$995.2	N. America
Healthcare Technology	Medidata Solutions Inc.	\$82.0	N. America
	Global Health Ltd.	\$1.5	Asia Pacific
Biologicals	Amgen Inc.	\$994.5	N. America
	Amgen Inc.	\$986.6	N. America
	Biogen Idec Inc.	\$541.9	N. America
Pharmaceuticals	Pfizer Inc.	\$3,484.7	N. America
	Pfizer Inc.	\$3,232.1	N. America
	Pfizer Inc.	\$2,985.8	N. America
Diagnostics	Baxter International Inc.	\$496.0	N. America
	Becton, Dickinson and Company	\$493.5	N. America
	Baxter International Inc.	\$347.3	N. America
Equipment & Supplies	Inverness Medical Innovations Inc.	\$379.5	N. America
	McKesson Corp.	\$347.7	N. America
	McKesson Corp.	\$346.5	N. America
Therapeutics	Medtronic Inc.	\$548.1	N. America
	Medtronic Inc.	\$397.9	N. America
	Medtronic Inc.	\$296.6	N. America

Source: Capital IQ

Contact Information

Roy A. Salter

rsalter@saltergroup.com

Patrick A. Russo

prusso@saltergroup.com

Eric C. Briggs

ebriggs@saltergroup.com

The Salter Group

The Salter Group is known for its outstanding capabilities in rendering independent valuation opinions to acquirers, investors and lenders in a variety of financing and M&A transactions. The Salter Group has distinguished itself as a leading independent financial and strategic advisory firm with a specialty in business and intangible asset valuations, financial opinions, economic analysis, forecasting and transaction support. The breadth of our global practice includes a broad range of industries, companies, intellectual property assets and transactions.

Our extensive experience in developing asset and business forecasts, and assessing a company's value and viability in light of current industry trends and global market conditions, enhances the value of our transaction opinions (fairness, solvency and collateral valuation opinions), financial opinions (goodwill impairment and portfolio valuation opinions), tax-related opinions, financial and strategic analyses and transaction support services.

Life Sciences & Healthcare - Selected 2008 Highlights

 Tax Opinion	 Valuation Opinion	 Advisory Services	 Advisory Services	 Advisory Services	 Tax Opinion
--	--	--	---	--	--

THE SALTER GROUP

1840 Century Park East, Suite 400

Los Angeles, CA 90067

tel (310) 552-3774

fax (310) 552-3781

www.saltergroup.com

Sources of information utilized in the preparation of this newsletter include Capital IQ, Adams Media Research, MPAA, Veronis Subler, Price Waterhouse, Thompson Financial and Morningstar. 'EV' and 'Ent Val' mean 'Enterprise Value' which is obtained from Capital IQ. 'Net Revenue' or 'Net Sales' are computed as last twelve months' figures derived from filed financial statements. 'EBIT' means earnings before interest and taxes and also are calculated on a last twelve months' basis. 'EV/Sales' and 'EV/EBIT' are calculated as enterprise value divided by Net Revenue and EBIT, respectively. EV/Sales' and 'EV/EBIT' on pages 6 and 7 are calculated using the value weighted average. Cost of Equity is calculated using the capital asset pricing model ("CAPM") with the variables calculated as follows: the market risk premium was determined based on information from Morningstar, b is calculated using stock price information from Capital IQ over a two-year period relative to the native country's major index and adjusted for prospective expectations, and the risk free rate is calculated from the yield of a 10-year generic treasury bond in each country.

The Salter Group, LLC gathers its information from sources it considers reliable. The Salter Group does not guarantee the accuracy or completeness of the information provided within this publication. The views presented reflect the current judgment of the authors and are subject to change. The Salter Group makes no warranties, express or implied, regarding the accuracy of this information or the subjective views expressed by the authors. Officers, Principals, Employees and Affiliates of The Salter Group may have positions in the securities of the companies described. This newsletter does not constitute a recommendation with respect to the securities of any company discussed herein, and it should not be construed as such. The Salter Group and its affiliates may from time to time provide financial and strategic advisory services to these companies. The authors of this publication receive compensation from The Salter Group.